Venetoclax in Pre- and Post-Transplant Therapy
A Phase 1 Study of Adding Venetoclax to a Reduced Intensity Conditioning Regimen and to Maintenance in Combination With a Hypomethylating Agent After Allogeneic Hematopoietic Cell Transplantation for Patients With High Risk AML, MDS, and MDS/MPN Overlap Syndromes
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 100 patients (estimated)
- Sponsors
- Dana-Farber Cancer Institute
- Collaborators
- National Cancer Institute (NCI)
- Tags
- Allogeneic Stem Cell Transplant, Antimetabolites, BCL-2 Inhibitor, Chemotherapy, Hypomethylating Agents (HMA)
- Trial Type
- Treatment
- Last Update
- 1 week ago
- SparkCures ID
- 1600
- NCT Identifier
- NCT03613532
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.